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Depression in adolescents and young adults 
with cancer  
Eliza M. Park, MD; Donald L. Rosenstein, MD
Adolescents and young adults (AYAs) with cancer are 
at risk for depression due to disruptions in their de-
velopmental trajectory, greater physical symptom bur-
den, and increased likelihood of developing aggressive 
disease. Rates of depression and other psychological 
disorders are substantially higher in AYAs with cancer 
when compared with older adults. Psychiatrists caring 
for these patients must consider the age-appropriate 
developmental context of these patients along with 
familial and medical factors that may influence the 
presentation and treatment of depression. Previous 
research suggests that psychosocial interventions spe-
cifically designed for AYA patients are promising, but 
studies of psychopharmacology treatments for depres-
sion are lacking. There is a pressing need for prospec-
tive studies and controlled clinical trials that evaluate 
the optimal strategies for treating depression in this 
patient group.      
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Introduction
 Cancer and depression, considered separately, 
are responsible for enormous human suffering on a 
global scale. An estimated 169 million years of healthy 
life were lost due to cancer worldwide in 2008,1 and 
the World Health Organization (WHO) predicts that 
unipolar major depression will be the leading cause of 
disease burden by the year 2030.2 When cancer and de-
pression are comorbid, symptom burden and mortality 
are each magnified, as one disease complicates the man-
agement of the other. These challenges are particularly 
salient for adolescents and young adults (AYA), who 
have experienced increasing rates of both cancer and 
depressive disorders.3,4 
 Although most cancer patients are elderly, the in-
cidence of cancer in the AYA population continues to 
rise. These younger patients have unique psychosocial 
problems, including depression, and often require so-
phisticated clinical management.5 Despite these difficul-
ties, the scientific literature on the optimal psychiatric 
care of depression in AYA cancer patients is noticeably 
scarce. 
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The treatment of depression in patients with cancer is 
relevant to psychiatrists due to the frequency of mood 
disorders in this population and the negative conse-
quences of untreated depression on their medical and 
quality of life outcomes. For several reasons, oncology 
providers are becoming increasingly cognizant of the 
need to identify depression in their patients and refer-
ring them for psychiatric consultation. One important 
driver of this trend in the United States is the recent 
regulatory initiative of the American College of Sur-
geons Commission on Cancer, which mandates system-
atic psychosocial distress screening within accredited 
cancer programs.6 As this new culture of distress screen-
ing in oncology settings expands, we predict that sub-
stantially greater numbers of suspected depressed can-
cer patients will present for evaluation and treatment. 
Given the many challenges of patients with comorbid 
cancer and psychiatric illness, depression management 
of these patients requires psychiatric clinicians who can 
competently care for medically complex patients. As in-
creasing numbers of AYA cancer patients with depres-
sion are identified, more research on optimal treatment 
will become necessary.
 This review addresses important psychosocial and 
biomedical factors that are relevant to the diagnosis 
and treatment of depression in AYAs with cancer. We 
focus on the AYA population in active cancer treatment 
as well as AYA patients in cancer survivorship, due to 
the prevalence and importance of psychiatric disorders 
in both phases of the cancer continuum of care. 
Cancer in adolescents and young adults
Defining the AYA population in cancer care has been 
difficult, as a number of different age ranges have been 
used in published studies. Most clinical investigators and 
organizations, including the National Cancer Institute, 
consider the AYA population to include individuals be-
tween the ages of 15 and 39.4 Within the United States, 
there are nearly 70 000 AYA patients diagnosed with 
cancer each year and tens of thousands of additional 
AYA individuals who complete cancer treatment annu-
ally.4 These estimates do not include the large number 
of individuals who survived a pediatric oncology illness 
that was diagnosed under age 15, though it should be 
noted that a diagnosis of cancer is six times more likely 
in adolescents and young adults than it is in children 
ages 0 to 14.4 The long-term psychiatric consequences 
of childhood cancer survivors have been extensively 
studied and are both complex and beyond the scope of 
this review.7,8 
 Innovations in cancer care have led to dramatically 
improved survival rates for both young children and 
older adults with cancer. Improvements have been less 
robust for younger adults with cancer. In the United 
States, cancer remains the leading cause of disease-re-
lated death in the AYA population, outpaced only by 
death due to accidents, suicide, and homicide. Among 
individuals with acute lymphocytic leukemia, AYAs 
have 5-year survival rates of 50% as compared with 
80% among children.9 Across all cancer types, the an-
nual rate of improvement in 5-year survival for AYAs 
has been less promising, particularly for individuals 
with breast cancer and leukemias.10,11 
 Evidence also suggests that the underlying can-
cer biology may be different in younger versus older 
adults. Young adults disproportionately develop cer-
tain cancers—primarily lymphomas and leukemias, 
invasive skin cancer, genital tract malignancies, endo-
crine cancers, brain and spinal cord tumors, and breast 
cancer.10,12 They may also be more likely to present 
with advanced stage and aggressive disease, possibly 
due to inadequate insurance status, higher treatment 
burden, and limited treatment options.13 Compared 
with older women with breast cancer, young women 
are more likely to develop triple-negative basal-cell 
breast cancer, an aggressive form of the disease. In 
contrast to the overall decreasing rates of colorectal 
cancer incidence in the United States, rates of this di-
agnosis (as well as poorer outcomes) have actually in-
creased among the AYA population.14,15 
 AYA cancer patients also report higher symptom 
burden compared with older adults with the same 
cancer type. For example, younger women receiving 
chemotherapy endorse worse physical symptoms (eg, 
greater nausea and vomiting).16 Furthermore, multiple 
studies have demonstrated that younger age is associ-
ated with greater cancer pain throughout all phases of 
cancer—active treatment, survivorship, and advanced 
or incurable disease.17-21 Pain itself is associated with 
depression, and there likely exists a bidirectional rela-
tionship between greater pain symptoms and depres-
sion in the AYA cancer population.22 More broadly 
across all cancers, AYA patients report greater con-
cerns about body image and sexuality; fertility con-
cerns; and cognitive dysfunction,23 along with evidence 
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of more negative changes in quality of life and subjec-
tive distress.24 
Depression in AYA patients with cancer
Epidemiology
Among all individuals with cancer, psychiatric syn-
dromes are common.25 Rates of adjustment disorders 
with depression or anxiety symptoms vary widely, with 
prevalence ranging from 16% to 42%.26,27 Estimates of 
minor depression or dysthymia are 20% in all cancer 
patients.28 While imprecise, rates of all mood disorders 
are substantially higher among cancer patients than 
in the general population, with MDD occurring up to 
three times more frequently in cancer patients.29 Al-
though prevalence rates vary depending on the meth-
odology employed, recent large and rigorously con-
ducted studies in Europe estimate the point prevalence 
of major depressive disorder (MDD) between 5% and 
15% depending on the site of cancer.30,31 In compari-
son, a systematic review of community-representative 
studies suggests a global point prevalence of MDD of 
4.7%.32 In the United States, results from the National 
Comorbidity Survey Replication, a nationally represen-
tative survey using an expanded version of the WHO’s 
Composite International Diagnostic Interview to assess 
mental disorders, estimated the 12-month prevalence of 
MDD as 6.6% in adults.33
 Younger age is consistently associated with higher 
rates of psychological distress and psychiatric syn-
dromes in adults with cancer.34,35 However, specific dif-
ferences in rates of depression between AYA and non-
AYA cancer populations are varied due to differences 
in how cases of depression are identified in studies. One 
study that utilized data from the 2009 US population-
based Behavioral Risk Factor Surveillance System, 
which included AYA cancer survivors and non-cancer 
controls, reported that AYA cancer survivors reported 
poorer mental health twice as frequently as AYAs with-
out cancer.36 A recent Danish cancer registry study re-
ported substantially higher rates of hospitalization for 
depression in patients diagnosed with cancer compared 
with the cancer-free population. Patients 15 years and 
older were at highest risk for depression severe enough 
to warrant hospitalization within the first year follow-
ing a cancer diagnosis, and remained at elevated risk in 
subsequent years.37 
Clinical presentation 
Accurate estimates of depressive disorders occurring 
with cancer are difficult, in part, because of the diag-
nostic challenges in this group. The co-occurrence of 
physical symptoms such as fatigue, anorexia, and sleep 
disruption are common sequelae of an underlying ma-
lignancy or its treatment.38 Whether and how these so-
matic symptoms should be considered in the diagnosis 
of a depressive disorder remains a subject of debate. In 
addition, common perceptions among providers and 
patients that depression is an “expected” response to 
a cancer diagnosis or a life-limiting illness further ob-
scures accurate measurement of the prevalence of de-
pression. 
 There are several cancer-specific considerations that 
may influence the accurate and timely diagnosis of de-
pression in the AYA patient. Fatigue is one of the most 
common adverse effects of cancer therapy and can per-
sist for years after treatment completion. Among long-
term cancer survivors, younger age is more frequently 
associated with this adverse effect.39 Fatigue is also the 
most commonly reported somatic symptom among pa-
tients with depressive disorders who present to primary 
care providers. In a pan-European study of 1884 indi-
viduals, fatigue was as frequently reported as depressed 
mood among men and women who were currently de-
pressed.40
 Endocrinopathies not typically seen in AYA pa-
tients without cancer are not uncommon in patients 
with cancer, and frequently present with comorbid neu-
ropsychological symptoms. Consequently, treatment of 
the underlying endocrine disorder may lead to modifi-
cations in standard antidepressant regimens (see treat-
ment section, below). Among young women with breast 
and gynecological malignancies, many will experience 
chemical or surgical menopause due to treatment. 
Those with estrogen or progesterone receptor-positive 
tumors can expect chronic treatment with selective es-
trogen receptor modulators (tamoxifen) or aromatase 
inhibitors, which lead to reduction of estrogen in target 
tissues. Both classes of medications require long-term 
adherence to daily treatment and are associated with a 
variety of psychological, cognitive, and physical symp-
toms.41,42 Menopause itself is associated with a two- to 
fourfold increased risk of developing MDD, particular-
ly among those with vasomotor symptoms43 and sleep 
disruption.44 
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 Among men with testicular and prostate cancers, 
androgen deprivation therapy is associated with a 
variety of mood effects including affective lability, ir-
ritability, sleep disturbance, and fatigue. AYA patients 
who are survivors of prostate or testicular cancer with 
low testosterone levels are at elevated risk for depres-
sive disorders, though the data are equivocal regarding 
whether this is due to deficient testosterone or from the 
cancer and its treatment.45 In addition, chronic opioid 
therapy—commonly prescribed for AYA patients in 
active cancer treatment or survivorship—can lead to 
opioid-induced androgen deficiency (OPIAD). Higher 
doses (ie, 100 mg or more of oral morphine equivalents 
daily) may be more likely to induce hypogonadism, 
though all patients receiving chronic opioid therapy are 
at risk.46
 Hypothyroidism is a risk for AYA patients exposed 
to therapeutic doses of radiation to the cervical neck re-
gion. This complication includes patients with head and 
neck cancers, lymphomas, and cancers of the central 
nervous system. Thyroid dysfunction may also occur 
in AYA patients with histories of breast cancer treated 
with loco-regional radiation therapy.47 Although report-
ed incidence rates vary widely, it is estimated that 20% 
to 30% of patients with histories of cervical neck radia-
tion exposure are at risk of developing hypothyroidism, 
with peak occurrence during the first 2 to 3 years af-
ter completing therapy.48 The psychological symptoms 
of hypothyroidism are well known to psychiatrists, and 
any AYA cancer patient who received radiation and 
presents with depressive symptoms merits thyroid func-
tion testing.49 
 Patients who receive endocrine therapies, as well as 
those receiving any cytotoxic chemotherapy, common-
ly report chemotherapy-related cognitive symptoms. 
However, the magnitude of this effect is unclear, and 
treatment for these symptoms is not specific to cancer. 
Most studies utilizing formal neuropsychologic testing 
demonstrate a small-to-moderate negative impact on 
cognitive function in patients with chemotherapy expo-
sure as compared with healthy controls.50 Although che-
motherapy-induced cognitive changes are often subtle, 
they may influence an individual’s ability to maintain 
focus, organization, and memory, which can significantly 
impact quality of life as well as mood.51 
 There are also a growing number of cancer patients 
living with metastatic or incurable disease, and although 
estimates of the number of individuals in this group are 
unknown, they are expected to increase as advances 
in cancer treatment allow patients to live longer with 
incurable illness. For example, the 5-year survival rate 
for metastatic breast cancer, an incurable disease, has 
more than doubled over the past 30 years.52 Unsurpris-
ingly, the physical symptom burden is higher among pa-
tients with metastatic or other advanced cancers than 
in those who have completed cancer therapy.53 In a 
systematic review of somatic and emotional symptom 
prevalence of 25 074 patients with incurable cancer, the 
most common symptoms reported were fatigue, pain, 
lack of energy, weakness, and appetite loss, which oc-
curred in more than half of the sample.54 Many of these 
symptoms overlap with diagnostic criteria for MDD, 
which interferes with accurate diagnosis in these clini-
cal samples. Compounding these physical and affective 
symptoms is the burden of living with the existential 
threat of a shortened life. For patients just embarking 
on adulthood or in the prime of their family and work 
lives, the fear of cancer progression or recurrence can 
fundamentally color all aspects of their experience. 
Developmental disruptions
Young adults with cancer experience disruptions in 
their normal developmental trajectory. Whether the 
cancer is diagnosed during advanced school years, an 
early career transition, or the start of a family, interrup-
tions in expected life roles and responsibilities are ma-
jor sources of psychological, practical, and existential 
concern for these patients and contribute to depression. 
The developmental theorist, Erik Erikson, postulated 
that the two main developmental tasks for the AYA 
population are: Identity versus Role Confusion (13-19 
years); and Intimacy and Solidarity versus Isolation (20 
to 39 years). During adolescence, individuals struggle 
to develop their identity. Peer relationships and social 
interactions become the predominant activities during 
this stage. As individuals mature into young adults, sig-
nificant friendships and romantic relationships become 
the defining features of development. Young adults who 
are successful are able to form stable, long-lasting, mu-
tually caring relationships. Those who are unsuccessful 
with this task are at risk for feeling isolated, lonely, and 
depressed.55 
 AYA patients diagnosed with cancer frequently con-
front the loss of an imagined future for themselves that 
can, in turn, precipitate a grief reaction regarding cur-
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rent and anticipated cancer-related losses. These losses 
often include the ability to bear biological children and 
delays in achieving other core developmental mile-
stones. Serious medical illness often requires increased 
dependence from others after reaching previously 
achieved developmental tasks, conformity to medical or 
caregiver expectations, and social isolation from peers, 
all of which can directly challenge the need to estab-
lish autonomy and identity in older adolescents. Among 
young adults, a life-threatening illness threatens the es-
tablishment or maintenance of romantic relationships. 
For both adolescents and young adults, concerns about 
cancer recurrence, long-term treatment side effects (eg, 
sexual dysfunction, infertility, body image changes, fi-
nancial and occupational difficulties, and disruptions to 
peer and romantic relationships) may have dispropor-
tionate psychological effects.56 
Barriers to treatment
Most cancer patients with depression do not receive 
appropriate treatment for their mood disorder. A fail-
ure to appreciate the impact of depression on cancer 
care, ambiguity in diagnosis, and lack of access to ap-
propriate mental health services all contribute to this 
gap in care.57,58 Among AYA cancer patients, there are 
additional practical barriers that interfere with optimal 
depression management. These patients are less likely 
to receive medical care in the traditional primary care 
system where most patients without cancer receive 
treatment for their depression.59 Among all age groups, 
AYAs are less likely to have insurance and report low-
er earnings than other adults.60 Compared with adults 
without histories of cancer, AYA survivors are more 
likely to experience financial barriers and have low con-
fidence in managing their survivorship needs.61,62
Consequences of untreated depression
Untreated depression causes profound psychological 
suffering and impairments in quality of life. In patients 
with cancer, depressive disorders are also associated 
with multiple adverse cancer-related medical outcomes 
including refusal of adjuvant cytotoxic treatment, 
longer hospital admissions, and poorer adherence to 
prescribed treatment regimens.63-67 Although not de-
finitively established, several reports suggest that AYA 
cancer patients are less adherent to acute cancer treat-
ment and survivorship care as compared with children 
or older adults. While there are multiple reasons for this 
difference, one critical factor is the patient’s develop-
mentally appropriate, but at times counterproductive, 
desire for autonomy.68,69 
 Depression itself appears to be an independent pre-
dictor of mortality in cancer patients. Three meta-analy-
ses suggest a 19% to 34% increased rate of mortality in 
cancer patients with depression symptoms.70-72 This find-
ing of increased mortality in depressed cancer patients 
is likely multifactorial in etiology. However, one specific 
concern, suicide, merits further discussion. 
Suicide risk in young adults with cancer
Cancer is a substantial risk factor for suicide. In a large 
cohort study based on the Swedish Population and 
Housing census, the relative risk of suicide within the 
first week of a cancer diagnosis was 12.6 as compared 
with all adult patients without a cancer; within the first 
year after diagnosis the relative risk was 3.1.73 Although 
less well studied, long-term cancer survivors are also 
at elevated risk of suicide, with reports suggesting in-
creased risk up to 8 to 10 years following the original 
cancer diagnosis.3 
 AYAs with cancer may be particularly susceptible 
to suicidal ideation and completed suicide. Self-inflict-
ed injury represents the second most common cause of 
death among individuals, both with and without cancer, 
aged 15 to 34 worldwide.74 In another cohort study of 
Swedish individuals, aged 15 to 30, a cancer diagnosis 
conferred a relative risk of 1.6 for suicidal behavior. The 
greatest period of risk occurred during the period most 
proximate to the initial cancer diagnosis.75 Other stud-
ies of AYA patients, focused on US populations, found 
that a cancer diagnosis is associated with a fourfold in-
crease in likelihood of suicide attempts in individuals 
ages 17 to 39 years. This association remained even after 
controlling for relevant variables such as alcohol use, 
depression, and demographic characteristics.76 
 In a small study of young adults with advanced can-
cer, more than 1 in 5 patients reported suicidal ideation. 
Interestingly, patient-oncologist alliance was found to 
be the strongest protection against suicidal ideation 
as compared with mental health interventions such as 
psychotherapy, psychopharmacologic management, or 
support group participation.77 These results suggest that 
distress and suicide screening among the medically ill 
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(rather than just behavioral health patients), a recom-
mendation from the United States Joint Commission, 
may improve detection of suicidality and therefore our 
ability to intervene in this at-risk population.78
Family considerations
Family composition and dynamics play a more promi-
nent role for the AYA cancer population. AYA patients 
may still be living with parents (or need to move back 
home) just when they are establishing important roman-
tic relationships. Other AYA cancer patients are in the 
early stages of their own parenting and child-rearing. 
The parental role and responsibilities for these patients 
may be an important contributor to their elevated dis-
tress. Parents with cancer are concerned about the im-
pact on their illness on their young families79 and rates 
of depression among all parents with cancer are high.80
 Data on advanced cancer patients with dependent 
children suggest they are more vulnerable to psycholog-
ical distress than similarly aged cancer patients without 
children. A longitudinal study of patients with advanced 
cancer found that parental status was associated with 
lower levels of peacefulness and having more worry as 
compared with nonparents. Their surviving spouse or 
caregivers also experienced significantly higher rates of 
depression, anxiety disorders, and complicated grief.81 
While this study did not specifically evaluate AYA can-
cer patients who are parents, the parental group was on 
average, 13.4 years younger than the nonparents. Data 
from a sample of bereaved widowers with dependent-
age children who lost a spouse to cancer indicate high 
levels of bereavement and depressive symptoms, even 
up to 2 years after the death of their wife.82 Multiple 
other studies have demonstrated the negative effect 
of a parental cancer diagnosis on minor children.83,84 
In sum, the effects of a cancer diagnosis for parents 
of dependent children—a population that principally 
encompasses the AYA population—can have negative 
and long-term ramifications for the entire family.
 Treatment of depression in AYA 
cancer patients
Psychosocial support and treatment
Existing interventions tailored specifically for the AYA 
population have focused on promoting achievement of 
developmental tasks, maintaining a sense of identity, 
and improving peer support. Preliminary evidence sug-
gests that peer support approaches may be more de-
sirable among AYA cancer patients than family-based 
interventions.85 
 The use of electronic and Internet media is com-
mon among AYA individuals. Consequently, Internet-
based resources are common ways that AYA patients 
with cancer identify and maintain peer support. These 
resources can vary from generalized support and in-
formation, as can be found at Stupid Cancer (www.stu-
pidcancer.org) and the Ulman Cancer Fund for Young 
Adults (http://ulmanfund.org), to Web sites focused on 
specific issues such as fertility, financial needs, and fam-
ily concerns. There are also several disease- and geog-
raphy-specific organizations for AYA cancer patients—
particularly for those with breast cancer—that provide 
more tailored information, resources, and opportunities 
for social networking. Both formal and informal online 
communities, ranging from large organizations such as 
Planet Cancer (http://myplanet.planetcancer.org) to 
individual blogs and personal Web sites, provide peer-
based support for AYA patients with cancer. 
 Despite the increasing interest in promoting the 
psychological well-being of AYA cancer patients and 
survivors, there remain large gaps in research and ser-
vice delivery. Promising developments are exercise and 
activity-based resources such as First Descents (https://
firstdescents.org) and Athletes for Cancer (www.athlet-
es4cancer.org). While these interventions may be ideal 
for many cancer survivors, they remain less helpful for 
those individuals who cannot participate fully in physi-
cal-based interventions. Consequently, there is a press-
ing need for resources for young adults with incurable 
illness or profound functional limitations.
Psychopharmacologic approaches
There are several general references that address prin-
ciples and strategies for the pharmacological manage-
ment of depression in patients with cancer.27,29,49,86,87 
Specific considerations for the AYA cancer population 
include therapies that minimize sexual dysfunction and, 
when possible, address comorbid somatic symptoms. 
Many AYA patients, both during active treatment and 
survivorship, remain on multiple other medications, and 
drug-drug interactions are highly relevant. For example, 
an average bone marrow transplant patient admitted to 
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the hospital receives 29 medications.88 Specific somatic 
symptoms that are targets for psychotropic treatment 
in AYA cancer patients include peripheral neuropathy 
and other pain syndromes, fatigue, anorexia, and hot 
flashes. A targeted symptom-reduction approach is rec-
ommended for these patients with high medical com-
plexity even if they do not meet full criteria for MDD. 
Clinical strategies that favor antidepressants with ad-
verse effect profiles matched to patients’ dominant 
cancer-related symptoms may be more appropriate for 
this group.89,90
 Specific agents that may work well for this popula-
tion include the use of duloxetine to address depres-
sion and other pain syndromes, such as peripheral 
neuropathy or musculoskeletal pain from aromatase-
inhibitors. Mirtazapine, an agent not commonly used 
in the noncancer AYA population, may be particularly 
helpful for treatment of weight loss, nausea, or insom-
nia. Venlafaxine is often used for treatment of comor-
bid depression and hot flashes, particularly in pre-
menopausal women who suffer from hot flashes and 
for whom treatment with p450 2D6 inhibitors might 
compromise the efficacy and clinical benefits of tamox-
ifen.91,92 Although the clinical impact of 2D6 activity in 
women taking tamoxifen remains a subject of ongo-
ing investigation,93 a population-based cohort study 
suggests that the inhibition of the hepatic cytochrome 
p450 2D6 isoenzyme, which converts tamoxifen into 
its active metabolite, endoxifen, with medications such 
as paroxetine may be associated with increased risk of 
death from breast cancer.94 
Conclusion
AYAs with cancer face multiple challenges to their 
emotional well-being that are distinct from those en-
countered by either younger or older patients with 
cancer. AYA patients remain an understudied and un-
derserved population despite the increasing prevalence 
of AYA cancer worldwide. A particularly important 
concern for AYA patients is the development of MDD. 
Knowledge of the unique risk factors for depression in 
this age group is important for psychiatrists who will be 
encountering these patients in greater numbers in the 
future. Prospective studies and controlled clinical trials 
are needed to advance optimal strategies for treating 
depression in this patient group. For example, studies 
to clarify the clinical relevance of p450 2D6 antidepres-
sant-mediated inhibition during tamoxifen treatment 
and the development of peer interventions for AYAs 
with advanced cancer and depression are sorely need-
ed. Psychiatrists have a unique and important role in 
the care of AYA patients suffering from both cancer 
and depression.  o
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La depresión en adolescentes y adultos jóvenes 
con cáncer
Los adolescentes y adultos jóvenes (AAj) con cáncer 
tienen un riesgo de depresión debido a las alteracio-
nes en su trayectoria evolutiva, al mayor impacto de 
los síntomas físicos y al aumento de la probabilidad de 
desarrollar patologías con agresividad. Los porcentajes 
de depresión y otros trastornos psicológicos son signi-
ficativamente mayores en los AAj con cáncer en com-
paración con los adultos mayores. Los psiquiatras que 
atienden a estos pacientes deben considerar el contex-
to del desarrollo apropiado a la edad de ellos junto con 
los factores familiares y médicos que pueden influir en 
la presentación y tratamiento de la depresión. La in-
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